Ginkgo Bioworks Reports Q3 2026 Financial Results and First Autonomous Lab Sale
Ginkgo Bioworks announced its third-quarter 2026 financial results, highlighting the first sale of its autonomous lab platform and reaffirmed cash-burn guidance.
Stocks · News reference
TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ginkgo Bioworks Director Catherine Cifuentes-Rojas Releases Biotherapeutics Go/No-Go Checklist
Dr. Catherine Cifuentes-Rojas, Director and Lead for Genetic Medicines and Biologics at Ginkgo Bioworks, has published a data-driven checklist designed to assist R&D teams in evaluating early-stage biotherapeutic programs.
Ginkgo Bioworks Director Catherine Cifuentes-Rojas Announces Reverse Mentorship Commitment
Dr. Catherine Cifuentes-Rojas, Director and Lead for Genetic Medicines and Biologics at Ginkgo Bioworks, has formalized a personal commitment to monthly reverse mentorship sessions with junior staff.
Ginkgo Bioworks to Review Q3 2026 Performance on November 5
Ginkgo Bioworks has announced it will host a presentation and Q&A session to discuss its third-quarter 2026 business performance on November 5, 2026.
Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.
Cathie Wood's Ark Invest has been buying Archer Aviation stock during its 62% decline, but the article examines Ark's track record of buying beaten-down stocks. Ark Innovation ETF has underperformed the S&P 500 by 110% over five years, with notable losses in past holdings like Teladoc (down 95%), Zoom (down 65%), and Ginkgo Bioworks (down 98%). The article cautions that investors should evaluate Archer based on its own business fundamentals and catalysts rather than Ark's historical performance.
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.